Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37466928.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1658 and PMC identifier 10530517.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
KRAS-mutated non-small cell lung cancer (NSCLC) is the most common genetically altered subtype of NSCLC, yet targeted therapies remain limited. Multiple studies have investigated combinations of MEK inhibitors with chemotherapy without success. Here we discuss these studies and novel approaches to targeting KRAS-mutated NSCLC. See related article by Gadgeel et al., p. 3641.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms